Levine EA, et al. - Researchers undertook a multicenter randomized trial to compare mitomycin to oxaliplatin HIPEC for appendiceal cancer. This first completed prospective randomized trial for cancer of the appendix demonstrated the feasibility of multicenter trials for this disease. Minor hematologic toxicity was evident with both mitomycin and oxaliplatin. However, compared to oxaliplatin in HIPEC, mitomycin resulted in slightly higher hematologic toxicity and lower QOL. Consequently, in patients with leukopenia, oxaliplatin could be preferred and in patients with thrombocytopenia, mitomycin could be preferred due to prior chemotherapy.